- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Merck & Company Inc (MRK)
The Merck&Co share price today is 144.67, view NYSE MRK stock exchange data. Track the latest Merck&Co share price with real-time updates on MRK stock performance including market cap, day range, 52-week range and dividend yield. Access MRK charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
143.47
147.62
52 wk Range
82.91
156.92
MRK is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
143.47147.62
52 wk Range
82.91156.92
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MRK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
160.87
Upside
+11.20%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
18 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
19 Buy
9 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 160.87
(+11.20% Upside)
Merck & Company Inc SWOT Analysis
Keytruda's Dominance | Explore Merck's reliance on cancer drug Keytruda, its impressive growth, and the looming patent cliff in 2028 that poses significant revenue challenges |
Gardasil Hurdles | Delve into Merck's strategic pause of Gardasil sales in China, impacting 2025 forecasts and raising concerns about inventory management and market dynamics |
Pipeline Potential | Learn about Merck's promising pipeline, including TROP2 ADC and KRAS inhibitors, as the company seeks to diversify beyond Keytruda and address future growth |
M&A Strategy | Analysts eye Merck's robust balance sheet and M&A potential, with acquisitions in the $1-15 billion range, as key to filling the post-Keytruda revenue gap |
Merck & Company Inc Earnings Call Summary for Q3/2026
- Merck Q3 2026: EPS $2.49 vs est. $2.09, revenue $18.1B vs est. $17.3B; shares rose 4.8% to $147.73 in pre-market trading.
- KEYTRUDA sales up 6% to $8.6B; WINREVAIR surged 94% to $694M; GARDASIL rose 14% to $2B, driving oncology and vaccine growth.
- Full-year guidance raised: revenue $66.8B-$67.3B, EPS $2.77-$2.82; expects modest 2027 growth despite $2B+ generic headwinds.
- Management confident in post-KEYTRUDA LOE transition, citing pipeline strength including sac-TMT, intismeran, and WINREVAIR expansion.
- Operating expenses up 12% to $7.4B on launch investments; $3B share buyback planned for 2026; gross margin held at 81.4%.
Last Updated: 29-10-2026, 08:40 pm
Read Full TranscriptEarnings
Latest Release
29-10-2026
EPS / Forecast
2.49 / 2.09
Revenue / Forecast
18.1B / 17.28B
Compare MRK to Peers and Sector
Metrics to compare | MRK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 145.5x | 33.4x | −0.3x | |
PEG Ratio | −1.68 | −0.56 | 0.00 | |
Price/Book | 8.5x | 1.6x | 2.6x | |
Price / LTM Sales | 5.3x | 1.6x | 2.8x | |
Upside (Analyst Target) | 11.2% | 0.0% | 67.2% | |
Fair Value Upside | Unlock | 0.0% | 10.1% | Unlock |
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Merck&Co (MRK) Share Price Today?
The Merck&Co share price today is 144.67.
What is the current Merck&Co (MRK) share price and day range?
As of 04-11-2026, the Merck&Co share price is 144.67, with a previous close of 144.67. The share price has ranged from 143.47 to 147.62 today, while the 52-week range spans from 82.91 to 156.92.
What Is the Merck&Co Market Cap?
As of today, Merck&Co market cap is 356.93B.
Does Merck&Co Pay Dividends? What's The Current Dividend Yield?
The Merck&Co dividend yield is 2.4%%.
What Is the Merck&Co (MRK) Share Price Target?
The average 12-month share price target for Merck&Co is 160.87, with a high estimate of 186 and a low estimate of 105. 19 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +11.20% Upside potential.
What Is Merck&Co's Earnings Per Share (TTM)?
The Merck&Co EPS (TTM) is 0.99.
When Is the Next Merck&Co Earnings Date?
Merck&Co will release its next earnings report on 02-02-2027.
From a Technical Analysis Perspective, Is MRK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
What Stock Exchange Does Merck&Co Trade On?
Merck&Co is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Merck&Co?
The stock symbol for Merck&Co is "MRK."
How Many Times Has Merck&Co Stock Split?
Merck&Co has split 5 times.
How Many Employees Does Merck&Co Have?
Merck&Co has 74000 employees.
What Is the MRK Premarket Price?
MRK's last pre-market stock price is 144.46. The pre-market share volume is 18,750.00, and the stock has changed by -0.21, or -0.15%.
What Is the MRK After Hours Price?
MRK's last after hours stock price is 144.69, the stock has changed by 0.02, or 0.01%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.